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Dengue virus encodes several interferon antago-
nists. Among these the NS5 protein binds STAT2,
a necessary component of the type I interferon
signaling pathway, and targets it for degradation.
We now demonstrate that the ability of dengue NS5
to associate with and degrade STAT2 is species
specific. Thus, NS5 is able to bind and degrade
human STAT2, but not mouse STAT2. This difference
was exploited to demonstrate, absent manipulation
of the viral genome, that NS5-mediated IFN antago-
nism is essential for efficient virus replication. More-
over, we demonstrate that differences in NS5 medi-
ated binding and degradation between human and
mouse STAT2 maps to a region within the STAT2
coiled-coil domain. By using STAT2/ mice, we
also demonstrate that mouse STAT2 restricts early
dengue virus replication in vivo. These results sug-
gest that overcoming this restriction through trans-
genic mouse technology may help in the develop-
ment of a long-sought immune-competent mouse
model of dengue virus infection.
INTRODUCTION
Despite its global health impact, there is currently no vaccine or
effective antiviral therapeutic available for dengue virus (DENV)
(Sampath and Padmanabhan, 2009; Whitehead et al., 2007).
One of the primary obstacles to developing such a tool is the
lack of robust animal models in which efficacy of a given vaccine
or drug can be tested prior to its administration in humans (Cha-
turvedi et al., 2005). Difficulties in developing mouse models for
DENV infection result mostly from the animal’s high resistance to
viral infection, manifested by a transient low viremia even after
high-dose challenges (reviewed in Yauch and Shresta, 2008).
Several studies have elucidated the critical role of type I inter-
feron (IFN) in mediating this resistance. Specifically, mice defi-410 Cell Host & Microbe 8, 410–421, November 18, 2010 ª2010 Elsecient in type I IFNa/b receptor (IFNAR) or in signal transducer
and activator of transcription 1 (STAT1) expression are compro-
mised in their ability to clear DENV at early time points. By way of
comparison, IFNGR1/ mice, which are IFNa/b signaling com-
petent but lack the type II IFNg receptor (IFNGR), remain nonvire-
mic upon DENV challenge. However, enhanced morbidity and
mortality can be achieved by infecting mice that are deficient
for both IFNAR and IFNGR (AG129 mice), indicating a greater
role for the type II IFN pathway at later stages postinfection
(Shresta et al., 2004b; Shresta et al., 2005). Though valuable
insight has been obtained from these mouse strains, their
immune deficiencies limit the scope of questions that can be
addressed, including questions on the efficacy of vaccines and
therapeutics.
The STAT protein family consists of seven members. Of the
seven, only STAT1 and STAT2 are required for the type I IFN
pathway as they (in association with IRF9)make up the transcrip-
tion factor complex interferon-stimulated gene factor 3 (ISGF3)
(Fu et al., 1990; Kessler et al., 1988). STAT domain organization
is conserved and includes an N-terminal domain, a coiled-coil
domain, a DNA-binding domain, an SH2 domain, and a transac-
tivation domain. With the exception of STAT2, the protein
sequence of the STATs is highly conserved between mouse
and human (Park et al., 1999; Paulson et al., 1999). STAT2 is
a frequent target for degradation by viral proteins including the
V protein of hPIV2 and the NS1 protein of RSV (Andrejeva
et al., 2002; Lo et al., 2005; Parisien et al., 2001).
DENV encodes several proteins which block the IFN produc-
tion or IFN signaling capabilities of the infected cell. These
include the NS2b-3 protease which limits IFN production (Rodri-
guez-Madoz et al., 2010), and the NS2a, NS4a, and NS4b
proteins which can independently inhibit the IFN signaling
pathway to some extent (Munoz-Jordan et al., 2003). In addition,
the NS5 protein was demonstrated to bind to STAT2 and tar-
get it for degradation through as-yet-unidentified mechanisms
(Ashour et al., 2009; Mazzon et al., 2009). This loss of STAT2
protein recapitulates what is observed during dengue infection
(Ashour et al., 2009; Jones et al., 2005). Curiously, the degrada-
tion activity but not the binding function of NS5 requires that
NS5 be expressed within the context of a polyprotein which
undergoes proteolytic processing for itsmaturation. Thismannervier Inc.
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during infection, though it remains unclear why it results in a gain
of function for this viral protein.
In this study we show that DENV NS5 is able to bind and
degrade human STAT2 (hSTAT2) in both human and mouse
cells, but is unable to bind or degrade mouse STAT2 (mSTAT2)
in either cell type. Furthermore, we show that DENV is sensitive
to the action of IFN in mouse cells, but not in human cells when
treatment occurs after infection, and that this phenotype corre-
lates with the species origin of STAT2. Finally, we map the ability
of NS5 to bind and degrade STAT2 to a region within the hSTAT2
coiled-coil domain. Taken together, we conclude that mSTAT2
is a restriction factor for DENV and that mutating this protein
through transgenic technology may result in an improved mouse
model for DENV infection.
RESULTS
NS5 of DENV Mediates Human STAT2 but Not Mouse
STAT2 Degradation
As mice are resistant to DENV infection, and this resistance
is dependent on a functioning IFN system, we were interested
in determining whether DENV could degrade mouse STAT2
(mSTAT2). To address this question, we generated clonal
STAT2/ mouse embryonic fibroblasts (MEFs) and U6A cells
(human cells deficient in STAT2 expression derived from the
nondeficient 2FTGH cell line) to stably express FLAG-tagged
versions of either hSTAT2 ormSTAT2. These cell lines expressed
similar levels of FLAG-tagged STAT2 protein and recovered
their ability to respond to IFN treatment (relative to their parental
cells) as measured by a bioassay (Park et al., 2003b) utilizing the
IFN-sensitive Newcastle disease virus expressing GFP (NDV-
GFP), (Figure 1A, see Figures S1A and S1B available online).
We next infected these cell lines with DENV and compared
the levels of FLAG-tagged STAT2 protein 24 hpi. As shown in
both Figure 1B and Figure 1D, DENV infection results in a loss
of hSTAT2-FLAG expression, but not mSTAT2-FLAG, in both
human and mouse cells, respectively. To rule out that this
was not a result of clonal selection, we utilized an NS5 transfec-
tion-based assay to demonstrate STAT2 degradation. We
have shown previously that transfection of NS5 in a form that
undergoes proteolytic processing is capable of decreasing
levels of overexpressed hSTAT2 in a manner sensitive to protea-
some inhibition, suggesting this is an active degradation process
(Ashour et al., 2009). For these experiments, we utilized an NS5
fused downstream of the E protein and processed by either
the viral protease (E-NS5-HA) or host deubiquitinating proteins
(E-Ub-NS5-HA). As demonstrated in Figure 1C, E-NS5-HA was
able to mediate loss of hSTAT2-FLAG but not mSTAT2-FLAG
in transfected U6A cells.
To determine if NS5 alone was able to degrade hSTAT2
without additional human host factors, we transfected BHK21
cells (hamster derived) with E-Ub-NS5-HA and either hSTAT2-
FLAG or mSTAT2-FLAG. As a negative control for this experi-
ment, we replaced full-length NS5 with NS5 containing an
N-terminal truncation of 277 residues that results in a loss of
hSTAT2-FLAG binding (E-Ub-NS5-HA 278-900) (Ashour et al.,
2009). Akin to the previous results, Figure 1E demonstrates
that E-Ub-NS5-HA expression results in loss of hSTAT2-FLAGCell Host &expression but not mSTAT2-FLAG expression. Similar results
were obtained when we cotransfected E-NS5-HA and NS2b-3-
HA with either hSTAT2-FLAG or mSTAT2-FLAG in STAT2/
MEFs (Figure S1C). Finally, we infected human U2A cells (IRF9
deficient) and U3A cells (STAT1 deficient) to determine whether
additional factors of the ISGF3 complex were required for DENV-
mediated hSTAT2 degradation, as is the case with some para-
myxoviruses that degrade STAT proteins (Horvath, 2004). Fig-
ure 1F demonstrates that hSTAT2 degradation occurs in the
absence of either of these proteins, indicating they are not
essential for this process. Thus the species specificity respon-
sible for STAT2 degradation observed occurs at the level of
STAT2 and is not due to additional host factors.
NS5 Associates with hSTAT2 but Not mSTAT2
As NS5 associates with hSTAT2 and this association is most
likely required for hSTAT2 degradation during infection, we per-
formed immune-precipitation experiments to determine whether
NS5-HA was able to associate with mSTAT2-FLAG. STAT1-
FLAG was used as a negative control for these experiments,
as it has been demonstrated to not associate with NS5. Immune
precipitation against the HA tag of full-length NS5 pulled down
hSTAT2-FLAG but notmSTAT2-FLAG (Figure 2A). Of note, levels
of hSTAT2-FLAG in the whole-cell extract (WCE) of samples
cotransfected with E-Ub-NS5-HA 1–900 are lower as compared
to samples cotransfected with E-Ub-NS5-HA 278–900, most
likely the result of active degradation (Figure 2A, panel 3). We
then performed the reciprocal immune precipitation within the
context of viral infection. As seen in Figure 2B, NS5 coprecipi-
tated only in the hSTAT2-FLAG-transfected samples. Of note,
levels of NS5 in theWCE of the hSTAT2-FLAG sample are signif-
icantly lower than NS5 levels in the remaining three WCE lanes
(panel three). We speculate that this could be due to the fact
that high levels of hSTAT2-FLAG in the cell most likely titrate
NS5 away from the replication complex, resulting in lower levels
of DENV infection.
Additional evidence of the species-specific difference in asso-
ciation between NS5 and STAT2 was observed through analysis
of NS5 localization in the presence of overexpressed hSTAT2 or
mSTAT2 in BHK21 cells. In the presence of endogenous levels of
hSTAT2, DENV NS5 is predominantly nuclear when overex-
pressed and during infection (Brooks et al., 2002; Forwood
et al., 1999; Kapoor et al., 1995). Given the nuclear localization
of NS5 and the predominantly cytoplasmic localization of unsti-
mulated STAT2, we hypothesized that high levels of STAT2
(capable of associating with NS5) may interfere with NS5 nuclear
localization. Figure 2C demonstrates that whereas NS5-GFP
and NS5-HA localize to the nucleus when coexpressed with
mSTAT2-FLAG, NS5-GFP and NS5-HA coexpressed with
hSTAT2-FLAG localize to the cytoplasm. Thus, through the use
of two independent assays, we conclude that NS5 association
with STAT2 is a species-specific event.
Finally, we examined the ability of NS5 derived from DENV1
(Western Pacific strain) to associate with hSTAT2-FLAG and
mSTAT2-FLAG. Similar to results obtained with DENV2 NS5
(16681), DENV1 NS5 coprecipitated hSTAT2-FLAG but not
mSTAT2-FLAG (Figure 2D). Thus, NS5 species specificity can
be extended to at least one other serotype and is not a feature
unique to DENV2 16681.Microbe 8, 410–421, November 18, 2010 ª2010 Elsevier Inc. 411
NS5
FLAG
Tubulin
hS
TA
T2
-
FL
AG mS
TA
T2
-
FL
AG
Em
pty
DENV +-+-+-
CB
Lane 1 3 4 52 6
2FTGH U6A
hSTAT2-
   FLAG
mSTAT2-
   FLAG
  WT 
MEFs
  STAT2 
KO MEFs
hSTAT2-
   FLAG
mSTAT2-
   FLAG
NFI o
N
NFI
A sllec esuoMsllec namuH
D
NS5
STAT2
Tubulin
2F
TG
H
U2
A
U6
A
DENV +-+-+-
U3
A
+-
F
Lane 1 3 4 5 7 82 6
*
 GFP
Tubulin
mSTAT2-FLAG
hSTAT2-FLAG
E-NS5-HA +-+-
++ - -
+ +--
Lane 1 3 42
STAT1-GFP
+ + + +
FLAG
+-+-
HA
Tubulin
E
Lane 1 3 42
STAT1-GFP
+ + + +
FLAG
GFP
NS5
Tubulin
DENV
hS
TA
T2
-
FL
AG m
ST
AT
2-
FL
AG
+-+-
W
T 
M
EF
+-
ST
AT
2-
/- 
M
EF
+-
Lane 1 3 4 5 7 82 6
FLAG
mSTAT2
hS
TA
T2
-
   
FL
AG
m
ST
AT
2-
   
FL
AG
E-Ub-NS5-HA 1-900
E-Ub-NS5-HA 278-900
+ - + -
 NS5-HA
 NS3-HA
278-900
1-900
NS2b-3-HA ++++
Figure 1. NS5-Mediated STAT2 Degradation Is Species Specific and Does Not Require Additional Species-Specific Host Factors
(A) Cells were treated with 100 m/mL type I IFN; 24 hpt, cells were challenged with NDV-GFP. Virus replication levels were recorded 12 hpi by live
microscopy.
(B) Human cells were infected with DENV at an moi of 10; 24 hpi, cells were lysed and levels of protein analyzed by SDS-PAGE and immune blotting.
(C) U6A cells were cotransfected with the given constructs; 24 hpt, cells were lysed and levels of protein analyzed by SDS-PAGE and immune blotting.
(D) Mouse cells were infected and processed as in (B).
(E) Cells were cotransfected with the given constructs; 24 hpt, cells were lysed and levels of protein analyzed by SDS-PAGE and immune blotting.
(F) Cells were infected with DENV at anmoi of 10; 24 hpi, cells were lysed and analyzed by SDS-PAGE and immune blotting. Asterisk denotes residual signal from
immune blot against STAT2. All western blots and microscopy data are representative of experiments performed several times. Upper arrows indicate FLAG-
tagged mSTAT2 expected migration. Lower arrows indicate FLAG-tagged hSTAT2 expected migration. See also Figure S1.
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of mSTAT2-FLAG
To determine if mSTAT2 expression would restore IFN signaling
in NS5-expressing cells, we performed IFN signaling reporter
assays in 293T cells. Increasing amounts of FLAG-tagged412 Cell Host & Microbe 8, 410–421, November 18, 2010 ª2010 ElseSTAT1, IRF9, and either hSTAT2 (hISGF3) or mSTAT2 (mISGF3)
were cotransfectedwith E-Ub-NS5-HA and the IFN-driven chlor-
amphenicol-acetyltransferase (CAT) reporter plasmid ISRE-
54-CAT-GFP. As a negative control, we used E-Ub-NS5-HA
278–900. In addition, we included a truncated form of NS5vier Inc.
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Dengue NS5 Is a Species-Specific IFN Antagonist(E-Ub-NS5-HA 10–900) that is deficient in degrading hSTAT2 but
retains hSTAT2 binding and IFN antagonism activity (Ashour
et al., 2009).
ISGF3 dose-dependent increases in GFP (Figure 3A) and CAT
(Figure 3B) activity were observed in both hISGF3- and mISGF3-
transfected cells in E-Ub-NS5-HA 278–900-containing samples.
E-Ub-NS5-HA 1–900 containing samples showed significant
inhibition of hISGF3-FLAG activity when hISGF3-FLAG plasmids
were cotransfected relative to the E-Ub-NS5-HA 278–900 nega-
tive control. E-Ub-NS5-HA 10–900 also significantly inhibited
hISGF3-FLAG activity at the 0.2 ng, 2.0 ng, and 20 ng amounts,
although to a lesser extent than full-length NS5, indicating that
binding to STAT2 inhibits ISGF3, possibly through inhibition
of STAT2 phosphorylation (Mazzon et al., 2009), but that
degradation further enhances this inhibition. In contrast to the
hISGF3-FLAG results, cells transfected with mISGF3-FLAG
showed intact signaling activity at all three doses in E-Ub-NS5-
HA 10–900-containing samples. Of note, E-Ub-NS5-HA 1–900
cotransfected with the lowest amount of mISGF3 showed
some inhibition of reporter activity. This may be due to a present
but low affinity of NS5 for mSTAT2, or it may represent the loss of
transcriptional activity contributed by the endogenous hSTAT2
(which would be targeted for degradation in the presence of
full-length NS5). FLAG-tagged STAT1, STAT2, and IRF9 protein
levels were undetectable at the 0.2 and 2.0 ng levels across all
samples (Figure 3C, top panels). Notably, opposing effects on
NS5 expression level were observed in samples dependent on
the ability of NS5 to associate with the cotransfected STAT2.
This may reflect differences in the stability of STAT2 associated
versus nonassociated NS5 and/or NS5 stability during IFN
signaling activation and will be followed up on in future studies.
Nevertheless, we conclude that NS5-mediated signaling antag-
onism is compromised in cells expressing mSTAT2. Further-
more, the fact that mSTAT2 expression was sufficient to
block NS5-mediated inhibition in these experiments suggests
that STAT2 is the primary target of the IFN antagonist activity
of NS5.
mSTAT2 Expression Inhibits Virus Production
in an IFN-Dependent Manner
As NS5 antagonist function is abrogated in cells expressing
mSTAT2, we next determined whether mSTAT2 expression
would have a deleterious effect on DENV production. For this
purpose, we measured virus titers in the supernatant of IFN-
treated hSTAT2 or mSTAT2 stable expressing cells. These
experiments were performed in both a human background (using
2FTGH cells and the STAT2-deficient U6A derivatives) and
a mouse background (using WT MEFs and the STAT2 KO deriv-
atives). Infected cells (moi of 0.1) were treated 12 hpi with
universal IFN and supernatant was collected 36 hpi. We chose
these conditions to reflect mainly the antiviral effects of IFN
in cells already infected with DENV. The use of universal IFN
allowed us to treat both mouse and human cells with the same
IFN. IFN treatment of 2FTGH cells resulted in less than 10% inhi-
bition in virus titer as compared to the untreated 2FTGH cells
(Figure 4A, see also Figure S2 for the virus titers obtained in these
experiments). A similar low level of IFN-mediated inhibition was
observed in the hSTAT2-FLAG stable expressing U6A cells.
This is in contrast to cells expressing mSTAT2-FLAG whichCell Host &show an 85% decrease in virus titer after IFN treatment (Fig-
ure 4A). We repeated these experiments using WT MEFs,
STAT2 KO MEFs, or STAT2 KO MEFs stably expressing
hSTAT2-FLAG or mSTAT2-FLAG. Whereas WT MEF cells and
mSTAT2-FLAG-expressing cells demonstrated 95% and 67%
inhibition of virus titer after IFN treatment, respectively, inhibition
was not observed in the STAT KO cells and hSTAT2-FLAG-
expressing cells (Figure 4B). Taken together, these results dem-
onstrate that mSTAT2 but not hSTAT2 inhibits virus replication
in an IFN-dependent manner. Furthermore, these results sug-
gest that STAT2 degradation is an important step in the virus
life cycle and is necessary for optimal virus infection in the pres-
ence of the IFN response.
mSTAT2 Is Required for Early Control of DENV
Replication In Vivo and in Mouse Macrophages
The importance of both the type 1 IFN receptor and STAT1 in
controlling DENV infection in mice has been shown previously
(Shresta et al., 2004b, 2005). In order to determine whether
mSTAT2 was also required, we monitored replication of a
mouse-adapted DENV, D2S10 (Shresta et al., 2006), in infected
WT and STAT2/ mice. Infections were performed by intrave-
nous (Figures 5A and 5B) or intracranial (Figure 5C) injection.
In the case of intravenous injection, viral RNA was detectable
in the lymph node (Figure 5A) and spleen (Figure 5B) of WT
mice at 8 hr postinfection, but was undetectable by 18 hr post-
infection. This in contrast to results obtained in the STAT2/
mice, where we could detect viral RNA in both organs up to
32 hr postinfection. Notably, at 60 hr postinfection, no virus
was detected in the spleen or lymph node of theWT or STAT2/
mice. This suggests that while STAT2 is important for control of
virus replication early in infection, it is not required at later time
points for clearance of dengue virus from these tissues. Similar
results were seen when we infected mice intracranially. Levels
of virus in WT mice were low at 24 hr postinfection and were
undetectable by 48 hr postinfection. However, we were still
able to detect DENV in the STAT2/mouse at up to 72 hr post-
infection (Figure 5C). In addition, no death was observed when
wemonitored survival past 7 days of one STAT2-deficientmouse
infected through the intravenous route and one STAT2-deficient
mouse infected intracranially (data not shown). Finally, we
wanted to know whether macrophages, a primary in vivo target
cell for DENV (Jessie et al., 2004), also required mSTAT2 for
controlling DENV replication. To test this, we infected primary
mouse monocyte-derived macrophages from the bone marrow
of WT (WT mBMDMs) or STAT2/ (KO mBMDMs) mice. No
virus could be detected in the WT mBMDM samples (Figure 5D,
squares). This is in contrast to DENV in the STAT2/mBMDMs,
which reached detectable levels of replication at 24 and 48 hr
postinfection (Figure 5D, triangles). These results indicate that
mSTAT2 is necessary for early control of DENV replication
in vivo and also in macrophages.
NS5 Interacts with the Coiled-Coil Domain of hSTAT2
To determine which specific region(s) of hSTAT2 is targeted by
NS5, we first used a functional assay based on an ISRE-CAT-
GFP reporter system that is activated by a construct encoding
hSTAT2-FLAG sequence fused downstream of IRF9 (Kraus
et al., 2003). As can be seen in Figure 6A, in contrast to theMicrobe 8, 410–421, November 18, 2010 ª2010 Elsevier Inc. 413
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Figure 2. NS5 Associates with hSTAT2 but Not mSTAT2
(A) BHK21 cells were transfectedwith plasmids encoding for FLAG-tagged STAT1 and STAT2, andHA-taggedNS5 proteins. Cells were lysed 24 hpt, and immune
precipitation was performed against the HA epitope.
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Figure 3. NS5 Inhibits hSTAT2-Mediated Signaling but Not mSTAT2-Mediated Signaling
(A) Cells were cotransfected with increasing amounts of hISGF3-FLAG (hSTAT2-FLAG, STAT1-FLAG, and IRF9-FLAG) or mISGF3-FLAG (mSTAT2-FLAG,
STAT1-FLAG, and IRF9-FLAG) plus ISRE-CAT-GFP, pCAGGS-Firefly luciferase, and either E-Ub-NS5-HA 278-900, E-Ub-NS5-HA 10-900, or E-Ub-NS5-HA
1-900; 24 hpt, cells were treated with 100 m/mL type I IFN. Reporter activity (measured by GFP signal) was visualized 48 hpt by livemicroscopy. Results are repre-
sentative of two independent experiments.
(B) Cells were transfected and IFN treated the same as in (A); 48 hpt, cells were lysed and CAT activity was measured. Fold induction of the ISGF3-FLAG-trans-
fected cells is calculated relative to the fold induction observed with ISRE-54-GFP-CAT-transfected IFN-treated cells versus untreated cells, both in the absence
of overexpressed ISGF3 components. This value is set as 1 and symbolized by the dashed horizontal line. Data were obtained from one experiment performed in
triplicate using independent sources for plasmids and cells. Bars indicate standard deviation of the samples. P values of the statistical differences calculated
between each sample (using unpaired, one-tailed, Student’s t test), are provided in the bottom panel. Those differences that were found to be significant
(p value% 0.05) between two samples are signified by an asterisk.
(C) Western blot analysis of one representative experiment. Lanes 1 and 12 represent the control samples that do not overexpress ISGF3 components or receive
IFN treatment. Lanes 2 and 13 represent the control samples that do not overexpress ISGF3 components and receive IFN treatment. Bands corresponding to the
predicted molecular weights of NS5 1–900 and 10–900 are indicated by the upper arrow in the second panel. Bands corresponding to the predicted molecular
weight of NS5 278–900 are indicated by the lower arrow of the second panel. Antibodies against FLAG, HA, GFP, and GAPDH were used.
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Dengue NS5 Is a Species-Specific IFN Antagonistnegative control Core-HA, NS5-HA is capable of preventing the
transcriptional activity of IRF9-hSTAT2-FLAG 1–851 (full-length
hSTAT2) or 100–851 (hSTAT2 lacking the first 99 residues).
However, this antagonist function is lost when we transfected
IRF9 fused to hSTAT2 residues 572–851 or 747–851. This indi-
cates that NS5 requires residues somewhere between hSTAT2(B) 293T cells were transfected with plasmids encoding for FLAG-tagged STAT1, S
24 hpi, cells were lysed and immune precipitation was performed against the FL
(C) Plasmids encoding for STAT1, hSTAT2, mSTAT2, and NS5 proteins were tran
(top panels) and subsequently fixed for immune staining using antibody against H
epitopes as well as DAPI stain to visualize DNA. Panels 2 and 3 are 103 images of
panels are from the same experiment (though not necessarily from the same field
plasmic and nuclear compartments.
(D) Same as (A). All western blots and microscopy data are representative of exp
Cell Host &region 100 and 572 for its antagonism. It is unlikely that the
loss of antagonism is due to defective folding of hSTAT2 result-
ing from large truncations, as the fusion protein is still capable of
activating transcription and western blot controls show com-
parable levels of IRF9-hSTAT2 expression in all transfections
(Figure 6B).TAT2, and IRF9 proteins; 24 hpt, cells were infected with DENV at anmoi of 10;
AG epitope.
sfected into BHK21 cells; 24 hpt, cells were live imaged for GFP fluorescence
A (secondary FITC fluorophore) and FLAG (secondary Texas Red fluorophore)
the cells after fixing and staining for NS5 and the STAT protein. The lower three
as panels 2 and 3) and have been enlarged for easy visualization of the cyto-
eriments performed several times.
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Figure 4. DENV Is Sensitive to mSTAT2 Expression
in an IFN-Dependent Manner
Human cells (A) or mouse cells (B) were infected with
DENV at an moi of 0.1; 12 hpi, cells were treated with
100 m/mL of type I IFN; 36 hpi, supernatant was collected
and levels of virus were measured by titration in Vero cells.
Percent inhibition is measured relative to the levels
achieved in the same cell line not treated with IFN (see
the Experimental Procedures). No virus was detected at
the 0 hour time point. Data was obtained from three inde-
pendent experiments and bars indicate standard deviation
of the samples. ANOVA results (Bonferroni multiple com-
parison test) are presented on the lower panels. Ns, no sig-
nificance. ***, extremely significant (p value < 0.001). **,
very significant (p value 0.001–0.01). See also Figure S2.
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and mSTAT2 sequence. Portions of the N terminus of mSTAT2-
FLAG were replaced with the homologous region of hSTAT2
(h/mSTAT2). As expected, immune precipitation against the
FLAG epitope of mSTAT2 failed to pull down NS5-HA (Figure 7A,
lane 3). IP of h/mSTAT2 containing the first 181 residues of
hSTAT2-FLAG (h/mSTAT2-FLAG 1–181) did not pull down
NS5, indicating that the first 181 residues of hSTAT2 were
not sufficient for interaction (Figure 7A, lane 4). However,
h/mSTAT2-FLAG expressing the first 301 residues of hSTAT2
coprecipitated NS5 (Figure 7A, lane 5). Thus, species-specific
sequence between residues 181 and 301 is required for interac-
tion with NS5.
To determine whether the h/mSTAT2-FLAG constructs that
could bind to NS5 resulted in them becoming susceptible to
NS5-mediated degradation, cells were cotransfected with the
h/mSTAT2 construct and either E-Ub-NS5-1–900 or E-Ub-NS5-
278–900. As expected, mSTAT2-FLAG in this assay showed no
detectable changes in protein level upon cotransfection with
E-Ub-NS5-1–900-HA as compared to the negative control (Fig-
ure 7B, lane 4 versus lane 3). Similar results were obtained
with h/mSTAT2-FLAG 1–181 (Figure 7B, lane 6 versus lane 5).
However, cotransfection of h/mSTAT2-FLAG 1–301 with E-Ub-
NS5-HA 1–900 resulted in a significant decrease in h/mSTAT2
(Figure 7B, lane 8 versus lane 7). Therefore, the ability of
STAT2 to bind NS5 correlates with the susceptibility to NS5-
mediated degradation. We constructed additional h/mSTAT2
chimeras and placed them into the degradation assay. We
first generated m/h/mSTAT2-FLAG in which the internal mouse
STAT2 residues 181–301 were replaced with the analogous416 Cell Host & Microbe 8, 410–421, November 18, 2010 ª2010 Elsevier Inc.human sequence. As can be seen in Figure 7C,
this construct was susceptible to NS5-mediated
degradation. Finally, HA-tagged chimeras in
which only the first 200, 210, and 250 residues
of mSTAT2 were replaced with the analogous
hSTAT2 sequence were all susceptible to deg-
radation (Figure 7C, lanes 3–8). These data indi-
cate that mSTAT2 and hSTAT2 amino acid
differences between region 181 and 200 play
a role in NS5-mediated association and degra-
dation of STAT2.
We next generated a panel of chimeras where
the N-terminal portion of STAT1 was replacedusing increasing N-terminal sequence of hSTAT2 (chSTAT2/1).
ChSTAT2/1-FLAG 1–124, which expresses the first 124 residues
of hSTAT2 and the remaining 125–751 residues derived from
STAT1, failed to be pulled down by NS5-HA (Figure 7D, lane
2). Increasing the amount of N-terminal hSTAT2 sequence so
that we express the first 239 or 316 residues resulted in the ability
to coprecipitate the NS5-HA protein (Figure 7D). Thus, the map-
ped region in the h/mSTAT2 chimeras required for binding/
degradation (181–200) is consistent with the binding region
mapped using the STAT2/1 chimeras (124–239). This falls within
the coiled-coil region of hSTAT2, which encompasses residues
138–230 (Martinez-Moczygemba et al., 1997). We next placed
these chSTAT2/1 chimeras into the STAT2 degradation assay
(Figure 7E). ChSTAT2/1-FLAG 1–124 levels were not decreased
in the presence of NS5. STAT2/1-FLAG chimeras 1–239 and
1–316, which bind NS5, also failed to be degraded. This
suggests that additional hSTAT2 sequence downstream of the
first 316 residues is important for STAT2 degradation. These
sequences are shared with mSTAT2, as similar h/mSTAT2
chimeras are degraded (Figure 7B). Overall, our results indicate
that the N-terminal region of hSTAT2 is needed for interaction
with NS5, but that additional STAT2 specific sequences are
required for degradation.
DISCUSSION
In this manuscript, we have demonstrated that DENV NS5-
mediated antagonism of the IFN pathway is species specific
and is nonfunctional in the presence of mSTAT2, suggesting
that species specificity occurs at the level of hSTAT2 and is
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Figure 5. mSTAT2 Is Required for Control of DENV Production In Vivo and in Mouse Monocyte-Derived Macrophages
(A and B) WT and STAT2/ mice were infected intravenously with DENV2 DS210. Lymph nodes (A) or spleen samples (B) were collected and viral load deter-
mined by qPCR for NS5. Results are from a single experiment (n = 3 for each time point) and error bars indicate standard deviation. The p value for the effect of
genotype was 0.0001. Limit of detection in this assay was 0.03 copies/mg represented by the dashed line.
(C) WT and STAT2/mice were infected intracranially with DENV2 DS210. Brain tissue was collected and viral load determined by plaque assay in BHK21 cells.
The limit of detection was 0.05 PFU/mg. Results are from a single experiment (n = 5 for 24 hpi and 72 hpi, n = 6 for 48 hpi) and error bars indicate standard devi-
ation. The p value for the effect of genotype was 0.0001.
(D) Mouse bone marrowmonocyte-derived macrophages (mBMDMs) fromWT and STAT2/mice were infected with DENV2 16681. Supernatant was removed
and analyzed for virus titer. Limit of detection in this assay is 4 fluorescing foci units/mL (FFU/mL) represented by the dashed line. No virus was detected at the
0 hour time point. Data were obtained from one infection performed in triplicate, and bars indicate standard deviation of the samples. Statistically significant
difference (p% 0.05) was determined using Student’s t test (unpaired, one-tailed). ND, not detected.
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Dengue NS5 Is a Species-Specific IFN Antagonistindependent of additional species-specific host factors. While
additional host factors aremost certainly required, their identities
remain unknown, though we believe they will most likely include
components of the ubiquitin/proteasome degradation pathway.
DENV strain variation has been observed with respect to manip-
ulation of the IFN pathway (Umareddy et al., 2008). Importantly,
we have shown that the species-specific nature of NS5 associa-
tionwith STAT2 is not unique to DENV2 (strain 16681) and can be
extended to DENV1. Given the relatively high percentage NS5
sequence identity when comparing DENV2 to the other three
serotypes (77% for DENV1, 77% for DENV3, and 72% for
DENV4) (Khan et al., 2006), we surmise that our results could
extend to DENV3 and DENV4. We note that DENV encodes
multiple IFN antagonists including NS2a, NS4a, NS4b, and pro-
teolitically active NS2b-3 (Leitmeyer et al., 1999; Munoz-Jordan
et al., 2003, 2005; Rodriguez-Madoz et al., 2010), and while they
were not a focus for this study, their antagonist function may
influence species tropism as well.Cell Host &In addition, we note that DENV is not the only virus whose
replication is restricted by species-dependent differences of
STAT2 or the IFN pathway. PIV5, a member of the Paramyxovir-
idae family, utilizes its V protein to bind hSTAT2 and the E3 ligase
DDB1 (Precious et al., 2005; Ulane and Horvath, 2002). Consis-
tent with this, hSTAT2 transgenic knockin mice showed higher
levels of PIV5 replication in vivo (Kraus et al., 2008). In related
fashion, NDV replication in human cells is facilitated through
swapping the V protein with the influenza NS1 protein, an IFN
antagonist that functions in human cells (Park et al., 2003a).
Thus, the ability to antagonize the IFN pathway can be a limiting
factor in determining species host range.
The results we have obtained using WT and STAT2/ mice
demonstrate that mSTAT2 is important for efficient control of
virus replication in vivo and in primary macrophages. It is there-
fore likely that a STAT2-deficient cellular environment in vivo can
be achieved, permitting detectable early levels of DENV replica-
tion, after DENV infection in an mSTAT2/ mouse expressingMicrobe 8, 410–421, November 18, 2010 ª2010 Elsevier Inc. 417
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Figure 6. Residues Found within Region 100–572 of hSTAT2 Are Required for NS5-Mediated Inhibition of STAT2-Dependent Transcription
(A) Cells were cotransfected with plasmids encoding an ISRE-54-CAT-GFP reporter; pCAGGS-Firefly luciferase; the IRF9-hSTAT2-FLAG construct stated; and
either empty, NS5-HA, or Core-HA protein; 24 hpt, cells were lysed and analyzed for CAT activity. Percent activation is calculated relative to samples transfected
with ISRE-54-CAT-GFP, pCAGGS-Firefly luciferase, and empty plasmid with no IRF9-hSTAT2-FLAG construct. Data were obtained from three independent
experiments, and error bars indicate standard deviation.
(B) Western blot of one representative experiment from the reporter assay. Lysates were analyzed by SDS-PAGE and immune blot analysis.
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Dengue NS5 Is a Species-Specific IFN Antagonistendogenous levels of hSTAT2. Thus, although the substitution of
mSTAT2 by hSTAT2 certainly will not overcome all murine
restrictions of DENV replication, especially at late times of infec-
tion, it may be a first step toward the development of an immune-
competent mouse model, though it should be noted that the
remaining DENV restriction at late times in STAT2/mice might
be mediated by type II IFN, as this antiviral factor does not
require STAT2 for signaling, and it is known to contribute to
decreased disease in DENV-infected mice (Shresta et al.,
2004a, 2004b, 2005).
Finally, through the generation of STAT chimeras, we identified
two separate regions within STAT2 that contain sequences
required for NS5 association and NS5-mediated degradation.
Based on our results, we hypothesize that NS5 binds to the
N-terminal region of hSTAT2 and that an as-yet-unidentified third
protein containing E3 ligase activity is recruited to the complex
through a motif located at the N terminus of NS5. This protein
would then interact with the C-terminal half of STAT2, resulting
in STAT2 ubiquitin conjugation and degradation. Further investi-
gation of the cellular proteins required for STAT2 degradation in
the presence of DENV is necessary to test this hypothesis.
Our understanding of DENV pathogenesis has benefitted
greatly through the use of animal models. Specifically, through
utilization of several genetically engineered mouse strains, the
critical roles of the type I and type II IFN pathways inmurine resis-
tance to DENV infection have been elucidated (Shresta et al.,
2004b); we note that while both STAT1 and STAT2 activity
have been implicated in type III IFN signaling, it remains to be
seen whether the activation of this pathway influences DENV
replication (Dumoutier et al., 2003; Kotenko et al., 2003). Never-
theless, while the type I and type II IFN-deficient mice have
proven invaluable with respect to our understanding of some
aspects of dengue pathogenesis, their immune deficiencies limit
the scope of questions that can be addressed, particularly those
relevant to the development of vaccines and therapeutics. The
use of humanized SCID or NOD/SCID mouse strains has over-418 Cell Host & Microbe 8, 410–421, November 18, 2010 ª2010 Elsecome this barrier to some degree, though this approach requires
a degree of skill and time (An et al., 1999; Bente et al., 2005;
Blaney et al., 2002; Kuruvilla et al., 2007; Lin et al., 1998; Wu
et al., 1995). Therefore, the development of an immune-compe-
tent mouse strain that is susceptible to DENV infection is desir-
able. Given the results obtained in our study, we speculate that
initial resistance to DENV in mice results from an inability of
NS5 to associate with and target STAT2 for degradation. There-
fore, development of a transgenic mouse expressing a functional
chimeric STAT2 capable of being degraded by an NS5-depen-
dent mechanism could result in an immune-competent mouse
susceptible to early DENV infection.
EXPERIMENTAL PROCEDURES
Cells and Viruses
All cell lines used in this work were cultured in Dulbecco’s modified Eagle’s
medium supplemented with 10% fetal calf serum. All clonal cell lines were
generated by cotransfection of the STAT2 encoding pCAGGS plasmid and
pCDNA-zeo and subsequently selecting for zeocin resistance. Recombinant
NDV expressing GFP was grown in 10-day-old embryonated chicken eggs.
High-titer stocks of dengue virus (DENV2 16681) were obtained by passage
in C6/36 cells. DENV1 D2S10 was kindly provided by Eva Harris. All transfec-
tions were performed using Lipofectamine 2000 (Invitrogen). For derivation of
BMDMs from wild-type and STAT2 knockout mice (Park et al., 2000), cells
were isolated from the bone marrow and cultured for 5 days in RPMI 1640,
10% FCS, pencillin/streptomyocin, and 20% L929 conditioned media.
Plasmids and Antibodies
All DENV protein-encoding plasmids were generated in the pCAGGS (chicken
b-actin promoter) background. Primer sequences used in the generation of
these constructs are available upon request. Plasmids encoding human
STAT1 and STAT2 were a kind gift from Dr. Megan Shaw. Plasmid encoding
for human IRF9 was kindly provided by Estanislao Nistal-Villan. ISRE-54-
CAT-GFP reporter, pCAGGS-Firefly, and luciferase plasmids were kind gifts
from Dr. Luis Martinez-Sobrido. pCDNA-zeo was a kind gift from Dr. Ben
tenOever. Mouse STAT2 cDNA was kindly provided by Dr. David Levy. Anti-
bodies utilized for this manuscript include those raised against HA (Sigma),
FLAG (Sigma), STAT1 (BD), STAT2 (Santa Cruz SC476), mSTAT2 (Santavier Inc.
Figure 7. NS5 Binding Domain Maps to the N Terminus of hSTAT2
(A) Immune precipitation of FLAG-tagged STAT protein. U6A cells were cotransfected with NS5-HA and the FLAG-tagged STAT2 constructs stated; 24 hpt, cells
were lysed and immune precipitation performed against the FLAG epitope. Asterisks denote full-length hSTAT2-FLAG, which has a faster mobility in SDS-PAGE
compared to the h/mSTAT2-FLAG chimeras.
(B) BHK21 cells were transfected with the stated FLAG-tagged STAT2, STAT1-GFP, and NS5-HA-tagged constructs; 24 hpt, cells were lysed and protein levels
analyzed by SDS-PAGE and immune blotting using antibodies against FLAG, GFP, HA, and tubulin. Upper arrow indicates expected mobility of mSTAT2-FLAG
and chimeras, and the lower arrow indicates expected mobility of hSTAT2-FLAG.
(C) BHK21 cells were transfected with the stated FLAG-tagged STAT2 or HA-tagged STAT2, STAT1-GFP, and NS5-HA-tagged constructs; 24 hpt, cells were
lysed and protein levels analyzed by SDS-PAGE and immune blotting. Panel 2 and panel 3 are two different exposure times of the same HA blot.
(D) BHK21 cells were cotransfected with NS5-HA and FLAG-containing STAT constructs; 24 hpt, cells were lysed and immune precipitation performed against
the HA epitope.
(E) U6A cells were transfected with the FLAG-tagged STAT2, STAT1-GFP, and HA-tagged constructs; 24 hpt, cells were lysed and protein levels analyzed by
SDS-PAGE and immune blotting. Upper arrow indicates expected mobility of hSTAT2-FLAG and lower arrows indicates expected mobility STAT1-FLAG and
chimeras. All western blots are representative of experiments performed several times.
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Dengue NS5 Is a Species-Specific IFN AntagonistCruz SC839), GFP (Sigma), GAPDH (Research Diagnostics Incorporated), and
tubulin (Sigma). Rabbit antibody raised against DENV2 NS5 was generated by
serial injection of bacterially expressed and purified DEN2 NS5 protein.
In Vivo DENV Infection and Quantification from Organs
For intravenous delivery of DENV, 24 hr prior to infection, 12 WT C57BL/6 and
12 STAT2/ C57BL/6 mice were injected intraperitoneally with 200 ml anti-
DENV1 serum that has previously been shown to enhance DENV2 infection
(Balsitis et al., 2010). The mice were then infected with 106 pfu of a mouse-
adapted DENV2 strain, D2S10, via tail vein injection. Organs were harvested
at 8, 18, 32, and 60 hr. DENV2 copy number was measured by the PCR
Core Facility of Mount Sinai School of Medicine using a SYBR Green qPCR
assay and primers against DENV NS5 and three housekeeping genes
(rps11, b-actin, and a-tubulin). For intracranial delivery of DENV, 16 WT
C57BL/6 and 16 STAT2/ C57BL/6 mice were injected intracranially with
105 pfu of D2S10. Brains were harvested at 24, 48, and 72 hr postinfection.
The viral loads in the cleared homogenates were measured by plaque assay
on BHK21 cells. Statistical analysis was performed to analyze the effect of
genotype using two-way ANOVA (Bonferroni post-test). Values were log10
transformed to approximate Gaussian distribution. Values below the limit of
detection were substituted for the limit of detection value (for example, a value
of 0.025 in Figure 5Awould be replacedwith a value of 0.03), thus giving amore
conservative calculation of p value.
Virus Quantification from Cell Supernatant
DENV titer present in infected cell supernatant was calculated by overlaying
250 ml of 1 ml total volume serial dilutions of the supernatant onto Vero cells
and incubating for 2 hr at room temperature. Supernatant was then removed
and replaced with fresh media containing 1% agar. The infection was then
continued for 72 hr at 37C. Infected cells were then fixed and stained for
DNA (using DAPI) and for NS5 protein using anti-NS5 antibody and
a secondary anti-rabbit FITC fluorophore. The number of positive foci was
counted by eye under a fluorescent microscope. Infectious particles are
expressed as fluorescing foci forming units/mL (FFU/mL). The limit of detec-
tion value reflects the sensitivity obtained when titrating virus stocks of known
quantity alongside the infected cell supernatants (i.e., 1 FFU is observed with
250 ml of virus stock diluted to 4 FFU/mL). To calculate percentage of inhibition
of dengue virus replication in IFN-treated cells, the FFU/ml obtained in IFN-
treated samples was divided by the FFU/ml obtained in IFN untreated
samples, and this number was subtracted from 1 and expressed as percent.SUPPLEMENTAL INFORMATION
Supplemental Information includes two figures and can be found with this
article online at doi:10.1016/j.chom.2010.10.007.
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